Survodutide Purity: 131 Lab Tests Across 56 Identified Manufacturers
41 studies on Survodutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently tracks 131 published third-party lab tests of Survodutide across 56 identified manufacturers. Among reports with a positive numeric purity result, the average is 99.51%. Within this published corpus, 0 positive purity results were below 90%, and 5 reports showed measured quantity more than 10% below the label claim. These are batch-level observations, not guarantees of product identity, safety, or vendor quality.
Survodutide average prices
As of 2026-09-03, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 10 mg | $29.50 | $26.00–$32.50 | $2.95 | 3 sources · 3 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
We tested 131 Survodutide batches across 56 identified manufacturers
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
Within that total, 23 batches have unresolved manufacturer identity. They remain in corpus-level lab evidence and are excluded from named-manufacturer rankings.
Top 3 vendor evidence profiles for Survodutide
Eligible vendors have at least 2 deduplicated tests and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and test count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes tested batches, not every product or shipment, and is not an endorsement.
| Rank | Manufacturer | Tests | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 13 | 99.34% | 0 of 12 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → | |
| #2 | 7 | 99.58% | 0 of 6 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → | |
| #3 | 4 | 99.77% | 0 of 4 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Manufacturer identities are included with Pro. Batch counts and lab measurements remain visible.
Recent certificates: #99865 (99.8%) · #94666 (99.73%) · #78882 (99.83%) · #72448 (99.71%) · #71401 (99.9%) · #74272 (99.9%)
Survodutide studies and clinical research
-
Survodutide once-weekly achieves up to 13.0% body weight reduction in adults with obesity
**Survodutide** represents a significant advancement in **obesity** pharmacotherapy, offering a dual `glucagon receptor`-`GLP-1 receptor` agonism that appears to deliver greater weight loss than current `GLP-1R` mono-…
-
Survodutide, a dual GLP-1/glucagon receptor agonist, shows promise for obesity and MASH treatment
The emergence of **survodutide** as a potential dual `GLP-1R`/`glucagon receptor` agonist could significantly expand the therapeutic landscape for **obesity** and **MASH**. For individuals struggling with these interc…
-
Review clarifies Survodutide's dual-agonist mechanism and promising clinical performance for obesity and liver disease
A plain language review clarifies **survodutide's** dual-agonist mechanism and promising clinical performance for **obesity** and **liver disease**.
-
Survodutide 6.0 mg significantly reduces liver fat by 84% and body weight by 12.2% in obesity with MASLD
This phase 3 data positions survodutide as a highly promising therapeutic option for individuals with **obesity** and **MASLD**, potentially offering a dual benefit by addressing both conditions simultaneously. **The …
-
Survodutide Phase 3 SYNCHRONIZE-JP trial initiates, assessing 3.6/6.0 mg weekly for Japanese obesity.
This Phase 3 trial is critical for establishing the efficacy and safety of **survodutide** specifically for Japanese adults with obesity, a population often underrepresented in global trials. **The results will provid…
-
New Survodutide Formulations Compared for Bioequivalence in Overweight Adults
Establishing bioequivalence between different drug formulations is crucial for drug development. It ensures that any changes in formulation (e.g., for improved stability, manufacturing, or patient convenience) do not …
-
Survodutide Bioavailability Study Compares Three Formulations in Healthy Adults
Optimizing Survodutide's formulation is critical for its future development as a potential treatment for obesity and NASH. A formulation with improved bioavailability could lead to more effective dosing strategies, po…
-
Survodutide Phase 3 Trial Targets Weight Loss in Diabetics
If the results demonstrate significant efficacy, survodutide could represent a transformative new therapeutic option for individuals struggling with the dual burden of overweight/obesity and Type 2 Diabetes. As a dual…
-
Survodutide Phase 3 Study Tests Weight Loss in Chinese Adults
The successful outcome of this Phase III trial could represent a significant advancement in the treatment of overweight and obesity, particularly for the Chinese population, where specific therapeutic options are high…
-
Survodutide Phase III Study Targets Obesity Disease in Japanese Adults
If the results demonstrate significant efficacy and a favorable safety profile, Survodutide could represent a substantial advancement in the treatment landscape for obesity disease in Japan. This is particularly impor…
-
Study Assesses BI 456906 Absorption in People with Kidney Impairment
-
Setmelanotide Shows Significant Promise for Genetic Obesity in Phase 2 Trial
These Stage 1 results from the Daybreak trial provide compelling evidence for the efficacy of Setmelanotide as a targeted therapeutic option for patients with early-onset, severe obesity and hyperphagia driven by MC4R…
-
Cardiac Safety of Novel Obesity Drug BI 456906 Assessed in Phase 1 Trial
-
Survodutide Phase III Trial for Obesity and NASH Completes Enrollment
The successful completion of enrollment for this Phase III trial is a significant milestone in the development of new therapies for NASH and obesity. Given the limited treatment options for NASH, a condition affecting…
-
Survodutide's Safety and Uptake Explored in Chinese Adults with Overweight or Obesity
This Phase 1 study is crucial for the continued development of survodutide, as it provides foundational data on how the drug behaves in a specific ethnic population. Understanding the pharmacokinetics and safety profi…
-
Survodutide Phase 3 Trial Investigates Weight Loss in Non-Diabetic Adults
If the results demonstrate significant and sustained weight loss, survodutide could represent a major advancement in the treatment of obesity and overweight, offering a new, potent therapeutic option. This is particul…
-
Survodutide's Impact on Common Drug Levels in Overweight or Obese Individuals
-
Study Tests How Weight-Loss Drug BI 456906 Affects Contraceptive Levels
-
Survodutide Phase 3 Trial Reveals Participant Baselines for Obesity Treatment
This paper primarily details the demographic and clinical characteristics of the study population at the start of the trial. The cohort comprised a diverse group of individuals with obesity, with an average age of 49.…
-
Anti-Diabetic Agents Show Strong Histological Efficacy in MASH, Driven by Weight Loss
This comprehensive network meta-analysis provides compelling evidence that anti-diabetic agents are not only effective in managing diabetes but also hold significant promise for treating MASH, a condition with limited…
-
Survodutide: A Dual GLP-1/Glucagon Agonist for Cardiometabolic Health
Survodutide's dual agonism represents a significant advancement, offering a multi-faceted approach to treating complex cardiometabolic diseases by simultaneously targeting weight loss, glycemic control, and hepatic st…
-
Survodutide Phase 3 Trial Reveals Baseline Profile of Obesity and Type 2 Diabetes Patients
Understanding the baseline characteristics of participants in a large Phase 3 trial is crucial for interpreting the future efficacy and safety results, ensuring the findings are generalizable to the target patient pop…
-
Hepatic GCGR is Key for Superior Weight Loss with Survodutide Analog
This research boldly underscores the critical role of hepatic GCGR in mediating the profound metabolic benefits of dual GLP-1R/GCGR agonists like survodutide. Understanding this mechanism could lead to the development…
-
Survodutide Targets Brain's Appetite Centers Through Specialized Organs
This research provides crucial insights into the central mechanism of action for Survodutide, demonstrating its direct engagement with brain regions critical for appetite regulation. Understanding that Survodutide act…
-
New Amylin Agonist Shows Potent Metabolic Benefits Beyond GLP-1 Pathways
This research establishes selective amylin receptor agonism as a powerful new therapeutic strategy for metabolic diseases, potentially offering superior benefits over existing incretin-based therapies. The distinct me…
-
Survodutide's Cardiovascular Outcomes Trial: Baseline Patient Profile Revealed
-
Blueprint for Measuring 'Disease Modification' in Obesity Trials Using Survodutide Data
This blueprint provides a standardized, multi-faceted approach to evaluating the long-term efficacy of novel anti-obesity treatments like survodutide, moving beyond simple weight loss metrics. By focusing on disease m…
-
Comparing Glucagon Agonists and Resmetirom for Liver Disease Treatment
-
Simulation Optimizes Patient Engagement for Survodutide Obesity Trial
This proactive optimization of the SYNCHRONIZE™ Phase 3 program for survodutide is crucial for accelerating the development and availability of new obesity treatments. By identifying potential bottlenecks and effectiv…
-
Survodutide: A Dual Agonist with Promising Results for Obesity and MASH
This review underscores the significant therapeutic potential of survodutide as a novel treatment for both obesity and MASH, leveraging its unique dual GLP-1 and glucagon receptor agonism. Its ability to induce substa…
-
Comparing Survodutide Formulations for Body Uptake in Healthy Adults
Optimizing drug formulation is crucial for enhancing patient convenience, adherence, and ultimately, therapeutic efficacy for conditions like obesity and MASH. If Formulation B2 demonstrates superior or comparable bio…
-
Survodutide Shows Strong Potential for Treating NASH and Liver Fibrosis
This Phase II trial provides compelling evidence that Survodutide could be a highly effective and much-needed therapeutic option for NASH and liver fibrosis, addressing a significant unmet medical need. The observed d…
-
New Drug BI 456906 Explored for Obesity, Compared to Semaglutide
Understanding the specific receptor binding profiles of BI 456906 is a critical first step in evaluating its potential as a novel therapeutic agent for obesity. If BI 456906 demonstrates significant and distinct gluca…
-
Survodutide vs. Semaglutide: Comparing Energy Use and Fat Breakdown in Obesity
This Phase 1 study is critically important as it seeks to understand the fundamental metabolic mechanisms of survodutide, a novel therapeutic candidate for obesity. If survodutide demonstrates superior or distinct ben…
-
Survodutide Delivery: Comparing Syringe vs. Pen for Bioequivalence
Establishing bioequivalence between different delivery devices for Survodutide is a critical step for its future clinical development and patient accessibility. If the pre-filled syringe and pen deliver the drug equiv…
-
New Phase 2 Trial to Test Survodutide for Chronic Kidney Disease
If successful, this Phase 2 trial could represent a significant advancement in the treatment of chronic kidney disease, a condition with high morbidity and mortality. A drug that can effectively reduce albuminuria cou…
-
Survodutide Enters Phase 3 Trial for NASH/MASH Cirrhosis Treatment
-
Survodutide Phase 3 Trial Investigates Cardiovascular Safety in Overweight Individuals
This large-scale Phase 3 trial is crucial for understanding the long-term cardiovascular impact of survodutide, a novel anti-obesity agent. A positive outcome would establish survodutide as a safe and effective treatm…
-
Survodutide Phase III Trial Investigates Treatment for MASH and Liver Fibrosis
The successful outcome of this Phase III trial could represent a monumental step forward in treating MASH, a condition affecting millions globally with no current pharmacological cure. If Survodutide demonstrates sign…
-
New Survodutide Formulation Tested for Bioavailability in Healthy Adults
As this is an active, not-yet-recruiting Phase 1 study (NCT07221591), specific results regarding the relative bioavailability of the two survodutide formulations are not yet available. The primary objective is to asse…
-
Survodutide Dual Agonist Shows Promise for Obesity and Liver Disease
This study highlights Survodutide's potential as a groundbreaking treatment for obesity and MASH, leveraging a dual mechanism of action through GLP-1 and glucagon receptor agonism. Its ability to induce substantial we…
Research tools
Free, no account — handy when you're working with Survodutide.
